Trial Profile
Efficacy of dolutegravir in HIV-1 failing antiretroviral-experienced patients with previous exposure to first-generation integrase strand transfer inhibitor (INSTI)- PRESTIGIO
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Nov 2017
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 01 Nov 2017 New trial record
- 24 Oct 2017 Results published in the Journal of Antimicrobial Chemotherapy